Kornimate/medical-research-clean huggingface dataset:
comparison of device based inspiratory muscle training and thera-band resistive training in healthy adults

Conditions: Healthy Young Adults

Summary: this study aims to evaluate the impact of inspiratory muscle training and thera-band resistive training on pulmonary function and diaphragmatic strength of healthy adults. this trail investigate whether imt can improve pulmonary function and diaphragmatic strength of healthy adults as well as overall respiratory health.

inspiratory muscle training(imt) has been shown to improve respiratory muscle strength and endurance in various conditions. this study aims to explore the effects of imt specifically in healthy young adults. to assess whether a structured imt program improves diaphragmatic strength and pulmonary function in healthy adults. a randomized control trail involving 56 competitive young healthy adults will be conducted. the study duration will be 8 weeks, with assessments conducted at baseline , mid-point, and at the end of intervention. the imt group participate in 20 minutes of training session, 4 to 5 times per week, using power-breathe device. thera-band resistive training group participate in 15 minutes of training session, 3 times per week, using different colors of thera-band. this study aims to provide robust evidence on the benefits of imt for young healthy adults.

Eligibility criteria:
inclusion criteria: * both male and female participants. * 20 to 35 years * fev1/fvc ratio above 60% * non-smokers exclusion criteria: * acute illness within last 2 weeks * obese patients whose bmi greater than 30kg * patient with history of chronic airflow limitation or any diagnosed disease. * patient with acute infection.

Keywords: inspiratory muscle training thera-band resistive training healthy young adults
intra-operative variation in size of brain tumors after craniotomy

Conditions: Brain Tumor, Primary

Summary: we planned to evaluate the change in tumor dimensions of intraaxial parenchymal tumors after craniotomy by comparing the tumor size on intraoperative ultrasonography (iousg) with pre-operative cect and cemri brain.

background: no previous study to determine the intraoperative changes in the tumor dimensions had been undertaken previously. objectives: we planned to evaluate the change in tumor dimensions of intraaxial parenchymal tumors after craniotomy by comparing the tumor size on intraoperative ultrasonography (iousg) with pre-operative cect and cemri brain. study design: this was a prospective observational study. participants: patients aged 15-65 years undergoing surgery at skims for intraaxial parenchymal intracranial tumors were included. methods: standard pre-operative cect and cemri brain were done to measure tumor dimensions and compared with iousg.

Eligibility criteria:
inclusion criteria: * all patients above the age of 15 years conferring to grade i and ii of american society of anesthesiologist (asa) physical status classification system, undergoing elective craniotomy with intracranial tumor excision were included in this study. patients with or without any neuro-deficit were also included. only those patients in whom all the tumor dimensions could be defined with precision on pre-operative cect, cemri and iousg were included in the final analysis. exclusion criteria: * patients' in whom there are multiple intracranial tumors (e.g. metastasis), deep seated tumors, inability to use iousg and in whom exact tumor dimensions cannot be defined either on pre-operative cect/cemri or on iousg were excluded.

Keywords: parenchymal brain tumors intraaxial brain tumors gliomas glioblastoma multiforme low grade glioma high grade glioma intraoperative ultrasound (ious) tumor surfacing tumor expansion contrast enhanced magnetic resonance imaging (cemri) brain contrast enhanced computed tomography (cect) brain
effect of soleus muscle push ups on oxidative stress and inflammatory markers, soleus endurance, and adipocytokines between type 2 diabetic, overweight/obese and normal weight individuals.

Conditions: Diabete Type 2; Obesity; Overweight

Summary: the study aims to investigate the impact of soleus push ups (spu) on soleus muscle endurance, oxidative stress markers, inflammatory markers and adipocytokines among people in the united arab emirates. this will be a pre-post intervention study with participants divided into three groups: lean normal metabolic profile, metabolically healthy overweight/obese, and patients with type 2 diabetes mellitus. assessment of anthropometry and body composition, soleus muscle endurance, blood tests for inflammatory markers, oxidative stress markers, and adipocytokines will be conducted pre and post-intervention.


Eligibility criteria:
inclusion criteria: * residents of uae, both males and females * ages 20-50 years * uncomplicated type 2 diabetic on meds, * normal lean bmi * overweight and obese exclusion criteria: * recent orthopedic surgery in the lls * pain in the lls starting from hips to ankle. * presence of varicose veins in the lls * present history of any cardiovascular condition * pregnant females * morbid obesity * diabetics undergoing insulin therapy only * smokers and alcohol consumption
evaluating interventions for intimate partner violence use in washington state

Conditions: Intimate Partner Violence

Summary: intimate partner violence (ipv), specifically physical and psychological aggression toward an intimate partner, represents a public health crisis that affects millions of americans each year. there currently exists very little evidence from randomized controlled trials for the effectiveness of abuser intervention programs designed to prevent and end perpetration of ipv in the general population. this is troubling considering that approximately half a million men and women are court-mandated to these programs each year. the investigators will conduct a randomized control trial (rct) investigating the efficacy of the strength at home (sah) intervention in reducing intimate partner violence (ipv). the overarching aim of this study is to test the efficacy of sah with court-involved-partner-violent men through an rct comparing those who receive sah with those who receive other standard ipv interventions offered in the state of washington (treatment as usual- tau). the specific aims are: 1.1: compare the frequency of physical and psychological ipv, the primary outcomes of interest, across conditions as reported by the male participants and their intimate partners across time 1 (baseline) and four 3-month follow ups (times 2-5). it is expected that greater reductions in ipv frequencies will be evidenced in sah than tau over the course of the year. 1.2: compare symptoms of ptsd, alexithymia, and alcohol use problems across conditions and assessment time points as reported by the male participants. it is expected that greater reductions in these symptoms will be evidenced in sah than tau over the course of the year. 1.3: compare treatment satisfaction across conditions as reported by the male participants across the four 3-month follow ups (times 2-5). it is expected that treatment satisfaction will be higher in sah than tau.


Eligibility criteria:
inclusion criteria: men: 1. identify as a man 2. provide consent for the research team to contact his intimate partner(s) for data collection purposes; 3. court-referred for ipv intervention in washington state women: 1. identify as a woman 2. were or currently are an intimate partner involved in an incident of ipv with a court-referred participant exclusion criteria: 1. demonstrates active psychosis that may interfere with their ability to participate in group 2. expresses prominent suicidal or homicidal ideation that requires hospitalization 3. does not possess proficiency in spoken english 4. periods of incarceration after study enrollment

Keywords: strength at home (sah) trauma-informed treatment as usual (tau) posttraumatic stress disorder (ptsd) alcohol use washington state
donepezil therapy and changes of symptoms and glucose metabolism in patients with dementia with lewy bodies (dlb)

Conditions: Dementia With Lewy Bodies (DLB)

Summary: the purpose of this study is to evaluate change of cerebral glucose metabolism by donepezil therapy and to associate change of glucose metabolism and symptoms.


Eligibility criteria:
inclusion criteria: dlb patients: * who fulfill the diagnostic criteria of dlb * 60 to 85 years old * right-handed * clinical dementia rating (cdr) ≧ 0.5 * mini mental state examination (mmse) score from 10 to 26 normal controls: * who are independent * who have no subjective or objective cognitive impairment * 60 to 85 years old * right-handed * mmse score over 24 exclusion criteria: dlb patients: * who have diabetes mellitus * who have pathological change on mri other than brain atrophy * who have complication or history of dementia other than dlb, psychiatric disease, and physical disorder that affect brain function * who have severe complication of cardiovascular, hepatic, renal, or other diseases unable to secure the safety * who have severe digestive ulcus * who have severe bronchitic asthma or obstructive lung disease * who have no caregiver who knows patient's condition well normal controls: * who have diabetes mellitus * who have taken donepezil before * who have abnormal findings on mri * who have complication or history of brain injury, psychiatric disease, and physical disorder that affect brain function

Keywords: dementia with lewy bodies (dlb) fdg-pet
a phase 2, single-arm, open-label study evaluating the efficacy and safety of single agent gs 1101 (cal 101) as therapy for previously treated chronic lymphocytic leukemia

Conditions: Chronic Lymphocytic Leukemia

Summary: the purpose of this study is to evaluate the effect of gs-1101 on the onset, magnitude, and duration of tumor control

this is a phase 2, multicenter, single-arm, controlled, clinical trial evaluating the efficacy and safety of the phosphatidylinositol 3-kinase delta (pi3k-delta) inhibitor gs-1101 (cal-101) as therapy for previously treated chronic lymphocytic leukemia. this clinical trial (study gs-us-312-0120) is a single-arm in which compliant subjects from gs us-312-0119 -arm b who experience progression of cll while receiving single-agent ofatumumab therapy are potentially eligible to receive single-agent, open-label gs 1101 therapy.

Eligibility criteria:
inclusion criteria: * participation in study gs-us-312-0119 * occurrence of confirmed progression of cll while receiving single-agent ofatumumab in study gs us 312 0119. * permanent cessation of study gs-us-312-0119 (single-agent ofatumumab) and no intervening or continuing therapy (including radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cll. * the time from permanent cessation of single-agent ofatumumab on study gs-us-312-0119 and the initiation of gs 1101 on study gs-us-312-0120 is no more than 12 weeks.

Keywords: chronic lymphocytic leukemia cll cal-101 ofatumumab
efficacy and tolerability of zolmitriptan nasal spray

Conditions: Migraine

Summary: the purpose of this study is to evaluate the effectiveness and tolerability (the ability not to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches for up to 12 weeks in adult subjects with migraine headaches


Eligibility criteria:
inclusion criteria: * subject has an established diagnosis of migraine headache, with or without aura * subject has a medical history indicating the presence of migraine attacks for at least 1 year before the start of the trial or a minimum of 2 and maximum of 6 migraine attacks per month on average for 3 months preceding the study * subject has non migraine headaches on fewer than 6 days each month for 3 months preceding the study exclusion criteria: * subject has history of basilar, ophthalmoplegic or hemiplegic migraine or serious neurologic condition associated with headache * subject has used a maoi within 2 weeks of randomisation or has been given ssri therapy or migraine prophylactic agent within 3 months of randomisation. subject requires treatment with propranolol or cimetidine or has had an intolerable or serious adverse event while using another triptan * subject has a history or symptoms suggestive of ischemic heart disease, coronary artery vasospasm or other significant underlying cardiovascular disease or clinically significant abnormalities seen on an ecg or uncontrolled hypertension

Keywords: zolmitriptan zomig migraine headache response headache headache pain
efficacy and safety of esoduo®

Conditions: Gastro Esophageal Reflux

Summary: clinical trial to evaluate the effects of esoduo® in controlling reflux symptoms related to the acid

the role of an esoduo® to control reflux symptoms related to the acid; a multicenter, open-labeled, phase 4 study \[racer study\]

Eligibility criteria:
inclusion criteria: 1. male or female aged ≥ 19 years 2. patients diagnosed with non-erosive reflux disease or mild erosive reflux disease 3. episode of heartburn the gerd symptom(either heartburn or gastric acid reflux) exclusion criteria: 1. surgery history on stomach or esophagus 2. barrett's esophagus (over 3cm), esophageal varices, esophageal stricture, esophageal achalasia, eosinophilic esophagitis, and primary motility disorders 3. patients diagnosed with grade c or grade d according to the la classification system during upper gastrointestinal endoscopy 4. patients with a history of malignancy within the past 5 years prior to the screening visit (visit 1) 5. patients who have taken prohibited concomitant medications within 14 days prior to the screening visit or require continuous administration of prohibited medications during the trial period. 6. clinically significant abnormal lab test 7. pregnant woman, breastfeeding woman.
a study of apremilast in children with oral ulcers associated with behçet's disease or juvenile psoriatic arthritis

Conditions: Behçet's Disease; Juvenile Psoriatic Arthritis

Summary: the primary objective of this study is to evaluate the long-term safety of apremilast in participants 2 years of age or older with oral ulcers associated with behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed study 20190530 or study 20190529.


Eligibility criteria:
inclusion criteria: * informed consent / assent obtained * must have completed week 52 on treatment on core study * age and sex specific body mass index (bmi) no lower in range than the 5th percentile on centers for disease control (cdc growth chart) * willing to adhere to study visit schedule and protocol requirements * must have acceptable benefit/risk for continued treatment with apremilast exclusion criteria: * answer "yes" to any question on c-ssrs at week 52 visit of core study * scheduled surgery or other interventions that would interrupt study participation * female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for 30 days after last dose * female participants planning to become pregnant while on study through 30 days after last dose * female participants of childbearing potential with positive pregnancy test at week 0 * known sensitivity to any products to be administered during dosing * not likely to be available to complete all protocol-required study visits

Keywords: oral ulcers behçet's disease juvenile psoriatic arthritis apremilast amg 407 otezla
brief intervention for icu patients with alcohol use disorders

Conditions: Alcohol Use Disorder; Critically Ill

Summary: patients non-electively admitted to intensive care units (icus) will be screened for eligibility. the investigators will include adult patients with risk level alcohol use, defined by audit-c score (\>5 for females, \>6 for males). informed consent will be obtained from the patient in the end or shortly after the icu treatment, when they have regained sufficient cognitive function. 600 patients will be randomized to receive either routine treatment or a brief intervention (bi). the bi includes a 20 minute discussion with pre-educated study personnel, option to discussion with a social worker and written material. primary outcome measure is the amount of alcohol used during the preceding week (g/week), at 6 and 12 months after study entry. the information will be obtained 1)in an interview by a study team member blinded for the intervention arm at 6 months 2) a letter of a telephone interview at 12 months. audit score, eq-5d and mortality will also be recorded. an interim analysis by an external reviewer will be performed after the primary outcome has been recorded for 200 patients,


Eligibility criteria:
inclusion criteria: * audit-c score \>5 (women) and \>6 (men) * non-elective admission to the icu exclusion criteria: * terminal illness (expected to survive less than 6 months), palliative care * diagnosed severe mental illness (psychos, severe depression, bipolar disorder, personality disorder) * cognitive disability * diagnosed dementia * impaired level of consciousness at discharge from the icu (expected to remain unchanged \>2 days * other substance abuse (excluding cigarette smoking) * ongoing treatment for alcohol dependency * insufficient language skills (finnish/swedish) * expected difficulty in getting contacted by mail or telephone (no permanent address or telephone in use)

Keywords: brief intervention alcohol alcohol use disorder intensive care unit critically ill audit
evaluation of clinical outcomes in an online teledermatology model for the management of psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to determine if an asynchronous online model of teledermatology can achieve similar clinical outcomes as compared to conventional in-office care for the management of psoriasis. the investigators also aim to determine the effects of this online care model on patient quality of life as well as patient and physician satisfaction. the investigators' hypotheses include the following: 1. compared to in-person visits, the online care model will result in similar clinical improvement in psoriasis disease severity. 2. compared to in-person visits, the online care model will result in similar improvements in quality of life. 3. providers and subjects in the online group will achieve a similar level of overall satisfaction as those in the in-person group.


Eligibility criteria:
inclusion criteria: * 18 years of age or older at time of consent, may be men or women. * requiring treatment of psoriasis for medically-indicated reasons. * capable of giving informed consent. * able to have their skin imaged by themselves or by family members. exclusion criteria: * non-english speaking individuals. * individuals lacking access to a digital camera and computer with internet connection.

Keywords: teledermatology telemedicine psoriasis
gastrointestinal and health-related quality of life outcomes in patients with autoimmune diseases treated with mycophenolate

Conditions: Autoimmune Disease

Summary: treatment with the immunosuppressive drug mycophenolate mofetil (mmf) may result in gastrointestinal (gi) complications in some patients. this study will 1) determine the proportion of patients with autoimmune diseases who are experiencing any gi complaints under mmf-based immunosuppressive treatment and 2) assess if a switch from mmf to enteric-coated mycophenolate sodium (ec-mps) results in improved gi and/or health-related quality of life outcomes.


Eligibility criteria:
inclusion criteria: 1. patients with autoimmune diseases; 2. receiving immunosuppressive therapy that includes mmf at time of study enrollment; 3. receiving immunosuppressive regimen that includes mmf at a stable dose for at least 1 month prior to enrollment. patients can only be enrolled into the study if it is expected that treatment will continue at the same dose until study end (6-8 weeks after enrollment). exclusion criteria: 1. if applicable, gi symptoms assumed or known not to be caused by mycophenolic acid (mpa) therapy (e.g. oral biphosphonates induced, infectious diarrhea); 2. women of child-bearing potential who are planning to become pregnant or are pregnant and/or lactating or who are unwilling to use effective means of contraception; 3. presence of psychiatric illness (i.e., schizophrenia, major depression) that, in the opinion of the site investigator, would interfere with study requirements; 4. current acute medical intervention or hospitalization; 5. presence of a medical condition not related to a gi event at time of visit, which requires immediate medical intervention. other protocol-defined inclusion/exclusion criteria may apply

Keywords: autoimmune disease, mycophenolate, gi problems
a phase 1 study to assess the effect of hepatic impairment on the pharmacokinetics of repotrectinib in advanced cancer patients

Conditions: Locally Advanced Solid Tumor; Metastatic Solid Tumor

Summary: this is a phase 1 study to evaluate the effect of moderate or severe hepatic impairment on the pk of repotrectinib in patients with advanced cancer.

this is a phase 1, multicenter, multiple-dose, open-label, nonrandomized study to evaluate the effect of moderate or severe hepatic impairment on the pk of repotrectinib following single and multiple dose administration of repotrectinib in patients with advanced cancer. this study will enroll 8 patients each with moderate hepatic impairment, severe hepatic impairment and normal hepatic function.

Eligibility criteria:
key inclusion criteria: 1. histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumor for which standard curative or palliative measures do not exist or are no longer effective. in case of hepatocellular carcinoma, the diagnosis should be based on at least 1 of the following: 1. the presence of at least 1 lesion, measuring ≥2 cm, with characteristic arterial enhancement and venous washout in the setting of liver cirrhosis and/or hepatitis b or c infection. 2. the presence of liver lesion(s) (as defined in inclusion criteria 3a) with alphafetoprotein ≥ 400 ng/ml. 3. tissue confirmation. 2. for patients with genetic ros1 or ntrk 1-3 gene fusion, tissue-based local testing should be documented. 3. biliary obstruction for whom a biliary drain or stent has been placed are eligible. 4. eastern cooperative oncology group performance status scores 0 to 2. 5. the patient must have no clinically significant change in hepatic disease status within the last 30 days before screening. 6. patient with ascites must not have a paracentesis within 3 months of screening. 7. protocol specified baseline hematology and kidney function laboratory values key exclusion criteria: 1. concurrent participation in another therapeutic clinical study. 2. symptomatic brain metastases or leptomeningeal involvement. 3. major surgery within 4 weeks. 4. clinically significant cardiovascular disease. 5. history of non-pharmacologically induced prolonged qt interval corrected for heart rate interval. 6. known active infections requiring ongoing treatment (bacterial, fungal, or viral, including human immunodeficiency virus positivity). 7. gastrointestinal disease or other malabsorption syndromes. 8. current use or anticipated need for drugs that are known to be strong cytochrome p450 (cyp) 3a inhibitors or inducers.